Therapeutic approach to Alzheimer's disease: current treatments and new perspectives

T Pardo-Moreno, A González-Acedo… - Pharmaceutics, 2022 - mdpi.com
Alzheimer's disease (AD) is the most common cause of dementia. The pathophysiology of
this disease is characterized by the accumulation of amyloid-β, leading to the formation of …

Photobiomodulation for hypertension and Alzheimer's disease

A Valverde, J Mitrofanis - Journal of Alzheimer's Disease, 2022 - content.iospress.com
Although the cause (s) of Alzheimer's disease in the majority of cases remains elusive, it has
long been associated with hypertension. In animal models of the disease, hypertension has …

Degradation of Alzheimer's amyloid-β by a catalytically inactive insulin-degrading enzyme

BR Sahoo, PK Panda, W Liang, WJ Tang… - Journal of molecular …, 2021 - Elsevier
It is known that insulin-degrading-enzyme (IDE) plays a crucial role in the clearance of
Alzheimer's amyloid-β (Aβ). The cysteine-free IDE mutant (cf-E111Q-IDE) is catalytically …

ADVANCES IN ALZHEIMER'S DISEASE: A MULTIFACETED REVIEW OF POTENTIAL THERAPIES AND DIAGNOSTIC TECHNIQUES FOR EARLY DETECTION

M Sharma, P Pal, SK Gupta - Neurochemistry International, 2024 - Elsevier
Alzheimer's disease (AD) remains one of the most formidable neurological disorders,
affecting millions globally. This review provides a holistic overview of the therapeutic …

Aggregation limiting cell-penetrating peptides derived from protein signal sequences

L Porosk, HH Härk, RN Bicev, I Gaidutšik… - International Journal of …, 2023 - mdpi.com
Alzheimer's disease (AD) is the most common neurodegenerative disease (ND) and the
leading cause of dementia. It is characterized by non-linear, genetic-driven …

Microglia as a Possible Alternative Therapeutic for Dementia

JS Alavez-Rubio… - Journal of Alzheimer's …, 2024 - content.iospress.com
Dementia is a syndrome in which there is deterioration in memory, behavior, and the ability
to perform everyday activities. Alzheimer's disease and vascular dementia are the most …

Gene expression of serotonergic markers in peripheral blood mononuclear cells of patients with late-onset Alzheimer's disease

M Neshan, A Campbell, SK Malakouti, M Zareii… - Heliyon, 2020 - cell.com
Abstract Serotonin or 5-hydroxytryptamine (5-HT) is primarily involved in the regulation of
learning and memory. Pathological changes in metabolism or functional imbalance of 5-HT …

Transdermal Therapeutic Systems for the Treatment of Alzheimer's Disease: A Patent Review

L Basso, SC Fagundes, T Staudt… - CNS & Neurological …, 2024 - benthamdirect.com
Background: Two classes of medications are used to treat Alzheimer's disease (AD);
donepezil, galantamine, and rivastigmine are acetylcholinesterase inhibitors, and …

La neuroplasticidad en la enfermedad de Alzheimer: una alternativa terapéutica a nivel molecular

NJN Gómez, RJR Morey, VRN Machado, MG León… - Medisur, 2020 - medigraphic.com
Los mecanismos de neuroplasticidad del organismo constituyen la base de disímiles
terapias que buscan potenciar tales efectos para alcanzar una relativa mejoría en gran …

β-Amyloid orchestrates factor XII and platelet activation leading to endothelial dysfunction and abnormal fibrinolysis in Alzheimer disease

KA García-Mejía, SJ Custodio-Chablé… - Alzheimer Disease & …, 2021 - journals.lww.com
Alzheimer disease (AD) is the most common form of dementia in humans. However, to date,
the cause of sporadic AD (SAD), which is the most frequent form, is still unknown. Although it …